These findings are in line with published data that showed cross-reactivity of ADA to originator infliximab and the biosimilars CT-P13 and SB2 in IBD patients, suggesting full-interchangeability regarding immunogenicity.9 This evidence concerns the gene ADA and inflammatory bowel disease.